| Varenicline use in patients with mental illness: an update of the evidence. | |
| | |
MedLine Citation:
|
PMID: 20166836 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: Patients with a psychiatric diagnosis have a higher prevalence of smoking compared to the general population. Varenicline is a first-line pharmacotherapy option to assist in smoking cessation. Clinical trials during drug development excluded patients with active psychiatric illnesses leaving the risks associated with varenicline use in this patient population unknown. AREAS COVERED IN THIS REVIEW: Literature published in English up to December 2009 were identified and include neuropsychiatric adverse drug events reported in pre-marketing trials and post-marketing surveillance, varenicline case reports, evidence surrounding the use of varenicline in patients with psychiatric diagnoses, and varenicline and suicidality. WHAT THE READER WILL GAIN: Although the risk of potential neuropsychiatric events is evident through voluntary reporting systems and reported cases in the literature, multiple studies and case reports support the use of varenicline in the mental health population. Reviewing the literature will enable clinicians to optimize patient care by weighing the risks and benefits associated with varenicline use against the risk of continued smoking. TAKE HOME MESSAGE: Cautious treatment initiation, patient education, and close follow-up, monitoring for mood and behavior changes during therapy are recommended, especially in the psychiatric setting. |
| | |
Authors:
|
Tara L Purvis; Leigh Anne Nelson; Scott E Mambourg |
Related Documents
:
|
22473266 - Spontaneous cerebrospinal fluid rhinorrhea through clival defect. 22478556 - Graphics for three-term contingencies. 22486196 - Early use of hemodialysis for active rewarming in severe hypothermia: a case report and... 9267376 - Postpartum psychosis induced by bromocriptine and pseudoephedrine. 3959196 - Megalourethra. 8600776 - Extramedullary hematopoiesis in pilomatricomas. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on drug safety Volume: 9 ISSN: 1744-764X ISO Abbreviation: Expert Opin Drug Saf Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-22 Completed Date: 2010-12-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101163027 Medline TA: Expert Opin Drug Saf Country: England |
Other Details:
|
Languages: eng Pagination: 471-82 Citation Subset: IM |
Affiliation:
|
VA Sierra Nevada Health Care System, Reno, USA. tara.purvis2@va.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Benzazepines
/
adverse effects,
pharmacology,
therapeutic use* Evidence-Based Medicine / methods*, trends* Humans Limbic System / drug effects, physiology Mental Disorders / chemically induced, drug therapy, psychology* Mood Disorders / chemically induced, diagnosis, psychology Patient Education as Topic / methods Quinoxalines / adverse effects, pharmacology, therapeutic use* Smoking / psychology*, therapy Smoking Cessation / methods* Suicide / psychology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Benzazepines; 0/Quinoxalines; 0/varenicline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Headache and medication overuse: are clinical case series appropriate to reveal differential risks o...
Next Document: Delayed-onset and recurrent limb weakness associated with West Nile virus infection.